Praxis Precision Medicines Reports $92.6 Million Net Loss in Q1 2026

Praxis Precision Medicines, Inc. reported a net loss of $92.6 million for the first quarter of 2026, compared to a net loss of $69.3 million for the same period in 2025. The company's total operating expenses increased to $105.9 million from $74.7 million year-over-year, driven primarily by a rise in research and development costs, which reached $78.0 million, up from $60.8 million. General and administrative expenses also saw a significant increase, rising to $27.9 million from $13.9 million. The net loss per share attributable to common stockholders was $3.20, slightly improved from $3.29 in the prior year.

In terms of financial position, Praxis reported total assets of $1.46 billion as of March 31, 2026, a substantial increase from $937.9 million at the end of 2025. This growth was largely attributed to an increase in cash and cash equivalents, which rose to $536.3 million from $357.3 million, and long-term marketable securities, which increased to $660.9 million from $326.8 million. The company's accumulated deficit also widened to $1.23 billion from $1.14 billion, reflecting ongoing investment in its clinical programs.

Strategically, Praxis has made significant advancements in its product pipeline. The company is preparing for the potential commercialization of ulixacaltamide and relutrigine, both of which have had New Drug Applications accepted for review by the FDA. The ulixacaltamide application is under review with a target action date of January 29, 2027, while relutrigine's target date is September 27, 2026. Additionally, Praxis is advancing its vormatrigine and elsunersen programs, with ongoing clinical trials expected to yield results in the coming quarters.

Operationally, Praxis has expanded its workforce, with an increase in employee headcount to support its growing research and development activities. The company has also engaged in various financing activities, including a follow-on public offering in January 2026 that generated approximately $621.2 million in net proceeds. This capital is expected to fund operations and clinical trials into 2028, although the company acknowledges the need for additional funding to support its growth strategy and potential commercialization efforts.

Looking ahead, Praxis anticipates continued operating losses as it invests in the development of its product candidates and prepares for potential market entry. The company remains focused on advancing its clinical trials and expanding its product pipeline, while also seeking to secure additional capital to support its operations. The future viability of Praxis will depend on the successful development and commercialization of its therapies, as well as its ability to navigate the complexities of the biotechnology market.